Q2 EPS Estimate for Agios Pharmaceuticals Reduced by Analyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at HC Wainwright lowered their Q2 2026 EPS estimates for Agios Pharmaceuticals in a note issued to investors on Tuesday, June 2nd. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will earn ($2.01) per share for the quarter, down from their prior estimate of ($1.58). HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.14) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.53) EPS, FY2026 earnings at ($6.77) EPS, FY2027 earnings at ($5.55) EPS, FY2028 earnings at ($4.65) EPS and FY2029 earnings at ($2.59) EPS.

Several other brokerages have also weighed in on AGIO. Bank of America lowered their target price on shares of Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, May 29th. JPMorgan Chase & Co. raised their price objective on shares of Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Monday, April 6th. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. The Goldman Sachs Group raised their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, April 1st. Finally, Citigroup raised their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and an average target price of $41.44.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock opened at $27.66 on Thursday. The firm has a market cap of $1.64 billion, a PE ratio of -3.81 and a beta of 0.59. The company has a 50-day moving average of $29.65 and a two-hundred day moving average of $28.74. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The firm had revenue of $20.75 million during the quarter, compared to analyst estimates of $13.30 million. The company’s quarterly revenue was up 137.7% compared to the same quarter last year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 3,141 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $109,024.11. Following the completion of the transaction, the chief financial officer owned 54,998 shares of the company’s stock, valued at approximately $1,908,980.58. This trade represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Tsveta Milanova sold 3,262 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $113,224.02. Following the completion of the sale, the insider directly owned 46,829 shares in the company, valued at approximately $1,625,434.59. This trade represents a 6.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 12,623 shares of company stock worth $438,144. 5.40% of the stock is owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at approximately $25,000. Assetmark Inc. raised its holdings in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 362 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals in the first quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at approximately $49,000. Finally, Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals in the third quarter valued at approximately $79,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.